The Most Comprehensive and Reliable Market Sizing and Forecasts in Infectious Disease IVD
Infectious disease testing comprises one of the largest and fastest growing applications served by the global in vitro diagnostics (IVD) industry. Infectious diseases are ailments caused by pathogenic microorganisms that invade the body, either directly or indirectly via afflicted carriers or contaminated sources. IVD tests for these conditions are designed to detect and identify the responsible pathogen, pinpoint its origin, and determine an appropriate antimicrobial therapy.
Forecasts from 2018 to 2031 for over 70 disease, technology and venue (lab-based POC) categories. Plus 21 regional& country markets.
Infectious disease IVD products include reagents, consumables, and instruments based primarily on immunoassays, molecular technologies, and conventional microbiology techniques. Specific types of tests are available for detecting hundreds of pathogenic conditions. The report examines the global demand for infectious disease IVD products, which is projected to increase as medical providers and healthcare organizations throughout the world heighten efforts to combat proliferating epidemic threats.
Kalorama’s Largest Study Focusing on Clinical Microbiology and Pathogen Detection Diagnostic Tests
This report, Infectious Disease Diagnostic Testing: World Market Analysis, examines the global market for infectious disease testing products. Specific applications analyzed and forecasted out to 2031 include:
- Healthcare-associated and opportunistic infections (C.diff, Sepsis, MRSA, VRE, Other HAI)
- HIV (molecular, immunoassay, POC)
- Hepatitis (molecular, immunoassay, POC, Type C, Type B, Other Types)
- Antimicrobial-resistant pathogens including bacteria, fungi, parasites, and viruses
- Human immunodeficiency virus (HIV) and hepatitis viruses
- Diseases related to women’s health (TORCH)
- Sexually transmitted infections (Chlamydia, HPV, Gonorrhea, HSV-2, Syphilis),
- Emerging, neglected, and tropical disease threats
- Lyme Disease
- Streptococcal Infections
- Fungal Disease, Parasitic Disease
- Dengue fever
- Influenza and RSV
- ID/AST (manual and automated)
- COVID-19 (immunoassay and molecular, analyst’s forecast to 2026)
Superior Geographic and Country Markets Coverage
Opportunities for infectious disease testing products vary widely between the developed and developing countries. Regions and countries covered with additional market breakouts include:
- Region: North America
- Region: Eastern Europe
- Region: Western Europe
- Region: Asia/Pacific
- Region: Africa/Middle East
- Region: Central and South America
- Region: Other Regions
- Country – US
- Country – UK
- Country – France
- Country – China
- Country – Germany
- Country – Italy
- Country – Mexico
- Country – Canada
- Country – Japan
- Country – South Korea
For each of these regions, the report contains market size and forecast for the following disease test markets within that region:
- Other Infections
- Total (w/o COVID)
Market Drivers, Health Statistics and Economics
The report examines market drivers, including external market influences that are promoting the development and use of improved infectious disease diagnostics. Public health officials worldwide have begun to recognize the global nature of infectious diseases – they are no longer solely a problem of developing countries but touch the very fabric of the social and economic welfare of countries in the industrialized world as well. Over the long term, aging populations and problems posed by infectious diseases will strain healthcare resources in many countries.
The report details the major competitors that are global market leaders in infectious disease testing products and technologies, including an overview and an outline of these company’s infectious disease IVD products:
- Abbott Laboratories
- Becton, Dickinson and Company (BD)
- bioMérieux Inc.
- Bio-Rad Laboratories, Inc.
- Bruker Corporation
- DiaSorin S.p.A.
- Hologic, Inc.
- Ortho-Clinical Diagnostics
- QIAGEN N.V.
- Quidel Corporation
- Siemens AG
- Thermo Fisher Scientific Inc.
The information presented herein is derived from publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author’s industry knowledge combined with literature searches and selected direct interviews with industry experts conducted previously.
Estimates in the report are based on an examination of epidemiological statistics, test pricing, annual reports of key competitors and regional sales, as well as Kalorama Information’s databases and economic composites. Forecasts presented for Eastern Europe were prepared prior to Russia’s invasion of Ukraine and its negative impact on the healthcare systems of both countries.